BIOCYTOGEN PHARMA. H YC1 (F:I54) — Market Cap & Net Worth
Market Cap & Net Worth: BIOCYTOGEN PHARMA. H YC1 (I54)
BIOCYTOGEN PHARMA. H YC1 (F:I54) has a market capitalization of $860.91 Million (€736.38 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #9619 globally and #1184 in its home market, demonstrating a 7.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOCYTOGEN PHARMA. H YC1's stock price €6.85 by its total outstanding shares 107501188 (107.50 Million). Also see how large is BIOCYTOGEN PHARMA. H YC1's balance sheet for a full breakdown of the balance sheet.
BIOCYTOGEN PHARMA. H YC1 Market Cap History: 2022 to 2026
BIOCYTOGEN PHARMA. H YC1's market capitalization history from 2022 to 2026. Data shows growth from $372.01 Million to $860.91 Million (22.18% CAGR). Also see I54 operating cash flow for how efficiently the company converts equity into cash flow.
BIOCYTOGEN PHARMA. H YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOCYTOGEN PHARMA. H YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest BIOCYTOGEN PHARMA. H YC1 stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.34x
BIOCYTOGEN PHARMA. H YC1's market cap is 0.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.72x
BIOCYTOGEN PHARMA. H YC1's market cap is 2.72 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $372.01 Million | $533.88 Million | -$601.95 Million | 0.70x | N/A |
| 2023 | $216.17 Million | $716.91 Million | -$382.95 Million | 0.30x | N/A |
| 2024 | $113.11 Million | $980.45 Million | $33.54 Million | 0.12x | 3.37x |
| 2025 | $471.30 Million | $1.38 Billion | $173.20 Million | 0.34x | 2.72x |
Competitor Companies of I54 by Market Capitalization
Companies near BIOCYTOGEN PHARMA. H YC1 in the global market cap rankings as of September 20, 2026. Review BIOCYTOGEN PHARMA. H YC1 tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to BIOCYTOGEN PHARMA. H YC1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
BIOCYTOGEN PHARMA. H YC1 Historical Marketcap From 2022 to 2026
Between 2022 and today, BIOCYTOGEN PHARMA. H YC1's market cap moved from $372.01 Million to $ 860.91 Million, with a yearly change of 22.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €860.91 Million | +82.67% |
| 2025 | €471.30 Million | +316.67% |
| 2024 | €113.11 Million | -47.67% |
| 2023 | €216.17 Million | -41.89% |
| 2022 | €372.01 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of BIOCYTOGEN PHARMA. H YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $860.91 Million USD |
| MoneyControl | $860.91 Million USD |
| MarketWatch | $860.91 Million USD |
| marketcap.company | $860.91 Million USD |
| Reuters | $860.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more